1. Home
  2. SNDX vs BFC Comparison

SNDX vs BFC Comparison

Compare SNDX & BFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • BFC
  • Stock Information
  • Founded
  • SNDX 2005
  • BFC 1894
  • Country
  • SNDX United States
  • BFC United States
  • Employees
  • SNDX N/A
  • BFC N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • BFC Major Banks
  • Sector
  • SNDX Health Care
  • BFC Finance
  • Exchange
  • SNDX Nasdaq
  • BFC Nasdaq
  • Market Cap
  • SNDX 1.1B
  • BFC 1.1B
  • IPO Year
  • SNDX 2016
  • BFC N/A
  • Fundamental
  • Price
  • SNDX $10.70
  • BFC $112.30
  • Analyst Decision
  • SNDX Strong Buy
  • BFC Buy
  • Analyst Count
  • SNDX 11
  • BFC 2
  • Target Price
  • SNDX $35.91
  • BFC $111.00
  • AVG Volume (30 Days)
  • SNDX 2.3M
  • BFC 25.4K
  • Earning Date
  • SNDX 05-05-2025
  • BFC 04-15-2025
  • Dividend Yield
  • SNDX N/A
  • BFC 4.66%
  • EPS Growth
  • SNDX N/A
  • BFC N/A
  • EPS
  • SNDX N/A
  • BFC 6.82
  • Revenue
  • SNDX $43,722,000.00
  • BFC $163,459,000.00
  • Revenue This Year
  • SNDX $263.44
  • BFC $12.55
  • Revenue Next Year
  • SNDX $129.44
  • BFC $5.79
  • P/E Ratio
  • SNDX N/A
  • BFC $16.51
  • Revenue Growth
  • SNDX N/A
  • BFC N/A
  • 52 Week Low
  • SNDX $9.66
  • BFC $77.00
  • 52 Week High
  • SNDX $25.07
  • BFC $117.24
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 38.98
  • BFC 57.43
  • Support Level
  • SNDX $9.67
  • BFC $112.80
  • Resistance Level
  • SNDX $14.24
  • BFC $119.04
  • Average True Range (ATR)
  • SNDX 0.93
  • BFC 2.62
  • MACD
  • SNDX -0.26
  • BFC 0.35
  • Stochastic Oscillator
  • SNDX 22.62
  • BFC 41.14

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About BFC Bank First Corporation

Bank First Corp is a United States-based company engaged in providing financial services provides a full range of consumer and commercial financial institution services to individuals and businesses including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.

Share on Social Networks: